ENLIVEN THERAPEUTICS, INC. Payments to Acquire Short-term Investments
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Payments to Acquire Short-term Investments of $47.56 million for the 12-month period ending 2021-12-31, per its 10-K filed 2023-02-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2023-02-10
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2021-12-31 was $17.79M, a 112.00% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2021-09-30 was $22.23M, a 59.00% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2021-06-30 was $3.81M.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for the quarter ending 2021-03-31 was $3.72M.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2021 was $47.56M, a 25.93% decline from fiscal 2020.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2020 was $64.20M, a 168.41% increase from fiscal 2019.
- ENLIVEN THERAPEUTICS, INC. payments to acquire short-term investments for fiscal 2019 was $23.92M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2021-12-31 | $17.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-10 | $40.02M derived: sum of 2 quarters · filed 2023-02-10 | $43.84M derived: sum of 3 quarters · filed 2023-02-10 | $47.56M 10-K · filed 2023-02-10 |
| 2021-09-30 | $22.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-25 | $26.04M derived: sum of 2 quarters · filed 2022-10-25 | $29.77M 10-Q · filed 2022-10-25 | $38.16M derived: sum of 4 quarters · filed 2022-10-25 |
| 2021-06-30 | $3.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-03 | $7.53M 10-Q · filed 2022-08-03 | $15.93M derived: sum of 3 quarters · filed 2022-08-03 | $29.91M derived: sum of 4 quarters · filed 2022-08-03 |
| 2021-03-31 | $3.72M 10-Q · filed 2022-05-06 | $12.11M derived: sum of 2 quarters · filed 2022-05-06 | $26.10M derived: sum of 3 quarters · filed 2022-05-06 | |
| 2020-12-31 | $8.39M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | $22.37M derived: sum of 2 quarters · filed 2022-03-15 | $64.20M 10-K · filed 2022-03-15 | |
| 2020-09-30 | $13.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $55.81M 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $41.83M 10-Q · filed 2021-08-06 | |||
| 2019-12-31 | $2.11M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-05 | $23.92M 10-K · filed 2021-03-05 | ||
| 2019-09-30 | $21.81M 10-Q · filed 2020-11-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |